Thalidomide toxicity in patients with AL (primary) amyloidosis.

被引：0
|
作者：
Palladini, G [1 ]
Perfetti, V [1 ]
Obici, L [1 ]
Merlini, G [1 ]
机构：
[1] Univ Pavia, Univ Hosp IRCCS Policlin San Matteo, Biotechnol Res Labs, Dept Biochem, I-27100 Pavia, Italy
来源：
BLOOD | 2002年 / 100卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1543
引用
收藏
页码：397A / 397A
页数：1
相关论文
共 50 条
  • [41] Peripheral vascular involvement in transthyretin cardiac amyloidosis. A comparative analysis with AL amyloidosis
    Stamatelopoulos, K.
    Delialis, D.
    Bampatsias, D.
    Tselegkidi, M. E.
    Petropoulos, I.
    Theodorakakou, F.
    Gavriatopoulou, M.
    Patras, R.
    Pamboucas, C.
    Kanakakis, J.
    Ikonomidis, I.
    Terpos, E.
    Trougakos, I. P.
    Dimopoulos, M. A.
    Kastritis, E.
    EUROPEAN HEART JOURNAL, 2021, 42 : 1798 - 1798
  • [42] Bladder amyloidosis.
    Miladi, M
    Peyromaure, M
    Thiounn, N
    Badoual, C
    Vieillefond, A
    Debre, B
    PROGRES EN UROLOGIE, 2003, 13 (02): : 297 - 299
  • [43] Aortic distensibility in primary amyloidosis. The contribution of cardiac involvement
    Moyssakis, I.
    Gialafos, E.
    Daskalaki, M.
    Nanis, L.
    Kikilias, V.
    Drosos, D.
    Votteas, V.
    JOURNAL OF HYPERTENSION, 2006, 24 : S74 - S75
  • [44] Preferential Vλ germline gene usage in primary amyloidosis.
    Perfetti, V
    Casarini, S
    Vignarelli, MC
    Palladini, G
    Rotundo, S
    Ascari, E
    Merlini, G
    BLOOD, 2000, 96 (11) : 153A - 153A
  • [45] Poor tolerance to high doses of thalidomide in patients with primary systemic amyloidosis
    Dispenzieri, A
    Lacy, MQ
    Rajkumar, SV
    Geyer, SM
    Witzig, TE
    Fonseca, R
    Lust, JA
    Greipp, PR
    Kyle, RA
    Gertz, MA
    AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS, 2003, 10 (04): : 257 - 261
  • [46] Electrocardiographic screening of cardiac amyloidosis in patients with primary AL amyloidosis
    Yamada, S.
    Yamamoto, Y.
    Ishizuka, M.
    Yamamoto, K.
    Takizawa, M.
    Uozumi, H.
    Ikenouchi, H.
    EUROPEAN HEART JOURNAL, 2016, 37 : 725 - 726
  • [47] Venetoclax induces sustained complete responses in refractory/relapsed patients with cardiac AL amyloidosis.
    Le Bras, Fabien
    Dupuis, Jehan
    Lemonnier, Francois
    Oghina, Silvia
    Bodez, Diane
    Ladaique, Amandine
    Maarek, Alizee
    Roulin, Louise
    Ferichou, Asma Beldi
    Frenkel, Valerie
    Haioun, Corinne
    Damy, Thibaud
    Belhadj, Karim
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [48] Detection of monoclonal free light chains by nephelometry in 262 patients with systemic AL amyloidosis.
    Lachmann, HJ
    Gallimore, R
    Gillmore, JD
    Smith, L
    Bradwell, AR
    Hawkins, PN
    CLINICAL CHEMISTRY, 2002, 48 (06) : A164 - A165
  • [49] Intermediate dose intravenous melphalan and dexamethasone treatment in 144 patients with systemic AL amyloidosis.
    Goodman, HJB
    Lachmann, HJ
    Bradwell, AR
    Hawkins, PN
    BLOOD, 2004, 104 (11) : 216A - 216A
  • [50] Elevated serum cardiac troponins are associated with shortened survival in patients with primary systemic amyloidosis.
    Dispenzieri, A
    Kyle, RA
    Gertz, MA
    Therneau, T
    Miller, WL
    Chandrasekaran, K
    McConnell, JP
    Burritt, MF
    Jaffe, AS
    BLOOD, 2002, 100 (11) : 604A - 604A
12345